Huabiao Chen, Ph.D.

Instructor in Investigation
Neurology, Mass General Research Institute
Instructor in Neurology
Harvard Medical School
Research Staff
Neurology, Massachusetts General Hospital
PhD Second Military Medical University School of Medicine 2005
In Dr. Chen’s laboratory a novel fusion protein consisting of the broadly immune activating mycobacterium tuberculosis-derived heat shock protein 70 (MTBHsp70) and the tumor antigen targeting activity of a single-chain variable fragment (scFv) binding mesothelin (MSLN) has been studied in its advantage of the immune-activating action of MTBHsp70 and the tumor-targeting activity of the scFv, which will yield anti-tumor responses against the broadest profile of tumor antigens. Meanwhile, the intratumoral microenvironment mediates induction of the programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on tumor cells and their interaction can silence the immune system. Dr. Chen’s team is working on the development of combination immune therapies, which involves the fusion protein to target and evoke an immune response to MSLN and the checkpoint blockade of PD-1/PD-L1 pathway to restore function of tumor antigen-specific cytotoxic T cells. The immune contexture in human tumors and infectious diseases, especially in HIV/AIDS, and its impact on clinical outcome has been being profiled that will help the design of clinical strategies to cure these diseases and development of the effective vaccines.
Research lab website Publications
Vaccine & Immunotherapy Center
CNY-Building #149
149 13th Street
Charlestown, MA 02129